--- title: "BioAtla, Inc. (BCAB.US)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/BCAB.US.md" symbol: "BCAB.US" name: "BioAtla, Inc." industry: "Biotechnology" datetime: "2026-05-22T01:35:13.285Z" locales: - [en](https://longbridge.com/en/quote/BCAB.US.md) - [zh-CN](https://longbridge.com/zh-CN/quote/BCAB.US.md) - [zh-HK](https://longbridge.com/zh-HK/quote/BCAB.US.md) --- # BioAtla, Inc. (BCAB.US) ## Company Overview BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California. | Item | Detail | |------|--------| | Industry | Biotechnology | | Exchange | US Market | | Website | [www.bioatla.com](https://www.bioatla.com) | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: D > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-05-21T04:30:18.000Z **Overall: D (0.77)** **Industry**: Biotechnology | Metric | Value | |--------|-------| | Industry Ranking | 316 / 385 | | Industry Median | C | | Industry Average | C | - **Style**: Value - Stocks where the company's main business is in a mature stage. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: D #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | -81.82% | | | Net Profit YoY | 18.20% | | | P/B Ratio | -0.16 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 5998072.12 | | | Revenue | 2000000.00 | | #### Multi Score Score: D | Indicator | Value | Rating | |-----------|-------|--------| | ROE | 275.38% | A | | Profit Margin | -2530.85% | E | | Gross Margin | 0.00% | E | | Revenue YoY | -81.82% | E | | Net Profit YoY | 18.20% | B | | Total Assets YoY | -77.63% | E | | Net Assets YoY | -6920.66% | E | | Cash Flow Margin | 73.46% | C | | OCF YoY | -81.82% | E | | Turnover | 0.09 | E | | Gearing Ratio | 535.55% | E | ```chart-data:radar { "title": "Longbridge Financial Score - BioAtla, Inc.", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "-81.82%", "rating": "" }, { "name": "Net Profit YoY", "value": "18.20%", "rating": "" }, { "name": "P/B Ratio", "value": "-0.16", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "5998072.12", "rating": "" }, { "name": "Revenue", "value": "2000000.00", "rating": "" } ] }, { "name": "Multi Score", "grade": "D", "indicators": [ { "name": "ROE", "value": "275.38%", "rating": "A" }, { "name": "Profit Margin", "value": "-2530.85%", "rating": "E" }, { "name": "Gross Margin", "value": "0.00%", "rating": "E" }, { "name": "Revenue YoY", "value": "-81.82%", "rating": "E" }, { "name": "Net Profit YoY", "value": "18.20%", "rating": "B" }, { "name": "Total Assets YoY", "value": "-77.63%", "rating": "E" }, { "name": "Net Assets YoY", "value": "-6920.66%", "rating": "E" }, { "name": "Cash Flow Margin", "value": "73.46%", "rating": "C" }, { "name": "OCF YoY", "value": "-81.82%", "rating": "E" }, { "name": "Turnover", "value": "0.09", "rating": "E" }, { "name": "Gearing Ratio", "value": "535.55%", "rating": "E" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | -0.12 | 80/385 | - | - | - | | PB | -0.16 | 464/385 | 43.46 | 41.64 | 38.76 | | PS (TTM) | 3.00 | 71/385 | 4.22 | 3.76 | 2.12 | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A | | 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A | | 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A | | 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A | | 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A | ## Institutional View ### Analyst Rating Distribution > As of 2025-11-28T05:00:00.000Z Total Analysts: **1** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 1 | 100% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 3.62 | | Highest Target | 500.00 | | Lowest Target | 500.00 | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/BCAB.US/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/BCAB.US/norm.md) - [Related News](https://longbridge.com/en/quote/BCAB.US/news.md) - [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/BCAB.US/filings.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**